CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells $107,504.08 in Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 1,343,801 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.08, for a total transaction of $107,504.08. Following the transaction, the insider now owns 17,618,618 shares in the company, valued at $1,409,489.44. The trade was a 7.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

CERo Therapeutics Stock Down 18.5 %

CERO opened at $0.06 on Monday. The stock’s 50 day moving average price is $0.13 and its 200-day moving average price is $0.21. CERo Therapeutics Holdings, Inc. has a one year low of $0.06 and a one year high of $12.80.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.